Hot Sales
Perfluoro-1,3-dim...
|
DOPA-Phe-Phe-OH
|
Ethyl...
|
(2R,3R,4S,5R)-2-(...
|
1-(Benzo[d][1,3]d...
|
1-(4-Isobutylphen...
|
(2-ethylbutyl...
|
(S)-2-ethylbutyl...
|
Perfluoro-1,3-dim...
|
DOPA-Phe-Phe-OH
|
Ethyl...
|
(2R,3R,4S,5R)-2-(...
|
1-(Benzo[d][1,3]d...
|
1-(4-Isobutylphen...
|
(2-ethylbutyl...
|
(S)-2-ethylbutyl...
|
Freight number | Package | Original price | Present price | Order quantity | Stock | describe |
---|---|---|---|---|---|---|
GN020787-25mg | 25mg | ¥0.00 | ¥400.00 | 6 | deliver goods within 1-2 days | |
GN020787-100mg | 100mg | ¥0.00 | ¥900.00 | 6 | deliver goods within 1-2 days | |
GN020787-1g | 1g | ¥0.00 | ¥3000.00 | 6 | deliver goods within 1-2 days | |
GN020787-5g | 5g | ¥0.00 | ¥9800.00 | 6 | deliver goods within 1-2 days |
Properties | |
Sales prompts | 阿斯利康的抗痛风新药,主成分为Lesinurad,FDA批准日期为2015年12月22日,化合物专利CN101083987已获授权,专利覆盖期至2025年.本品不对有专利限制的国家和地区销售,不得人用。 |
---|---|
Specification And Standard | |
Production And Usage | |
Packing And Storage | |
Safety | |
Spectrum And References | |
Contact Salesman |